The 2012 Molecular Diagnostics 5th. Edition Market DNA Probes and Biochips at RnR Market Research

Feb. 7, 2013 - PRLog -- Molecular diagnostics is becoming a dominant platform in clinical medicine and represents one of the fastest growing segments of the IVD market. As analyst Shara Rosen, R.T., MBA. details, in recent years years the number of assays introduced has been growing at a remarkable clip. This report, The World Market for Molecular Diagnostics (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) represents the fifth time that Kalorama has conducted a complete study into the market for molecular diagnostics.

Comprehensive Coverage of the Molecular Diagnostics Industry

The report not only contains current market data for business planning, it goes beyond the numbers to fully assess what is going on in the market and why. Since the last edition of this report, a lot has changed, and a lot has stayed the same. There is intense competition but also opportunities for entrants in some areas.

This comprehensive seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.

Request a Sample Copy of World Market for Molecular Diagnostics, 5th. Edition
@ http://www.rnrmarketresearch.com/contacts/request-sample?...

Request a Sample Copy of The 2012 Molecular Diagnostics Market: DNA Probes and Biochips
@ http://www.rnrmarketresearch.com/contacts/request-sample?...

More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and have agreed to pay for them. A desire for better and faster test results, a preference for tests that are aimed at the patent, renewed interest in IVD in general and more particularly in molecular IVD has led to the commercialization of a number of technological tools that make more sensitive and specific tests possible. Some of these technological innovations include cost-effective, multiplexed testing platforms coupled with high-powered software capabilities.

Molecular diagnostics is a complicated market that requires a thorough analysis to understand. Many reports make bold predictions which later are proved incorrect by market events. In this report, Kalorama Information provides revenues and market forecasts, but also looks deeply at some of the trends in the market and what might impact results in the future. The report summarizes what is working and what is not working in the past few years.

- Sequencing Hype and Reality: Innovations in DNA Sequencing, Key Players and its Future in Clinical Medicine
- Pharmacodiagnostics and Where it Stands in 2013
- The Latest Growth Numbers of LDTs, regulatory activity, and their impact on the Market
- IVD Directive Update
- Patent Issues
- Healthcare Reform, Accountable Care Organizations and Reimbursement Trends
- Improvements in Platforms
- Developments in ISH testing, Tissue Microarrays and Mass Spectroscopy
- Integrated Sample-to-Results Testing

Market size and forecasts in the report are for manufacturer’s revenues. Secondary and primary resources, including: trade publications, annual report and interviews with key executives in molecular diagnostics were used for this study.